DrugBiological
Zinlirvimab clinical trials
Also written 10-1074 and GS-2872.
- studies test it
- 16
- open now
- 2
- in phase 3
- 2
- first study started
- 2016
Keep track of what changes. Save the zinlirvimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2019 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 12
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Gilead Sciences (4) · Rockefeller University (4) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · University of Aarhus (1)
Often tested with
Tested in the same studies.
Teropavimab (9) · Lenacapavir (4) · Lafuvitug (4) · Antiretroviral Therapy (1) · VRC-01LS (1) · Nogapendekin alfa inbakicept (1) · MGN1703 (1) · PGT-121 (1)
Studies
Open first, then newest update. How each study uses zinlirvimab is read from its arms, and is right about nine times in ten.
Testing it · 16
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyRecruitingPhase 3Gilead SciencesNCT07682961Written as Zinlirvimab
- Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensRecruitingPhase 3Gilead SciencesNCT07683000Written as Zinlirvimab
- A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05612178Written as 10-1074-LS
- Antiretrovirals Combined With Antibodies for HIV-1 Cure In AfricaActive, not recruitingPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT06205602Written as 10-1074-LS
- Dual bNAb Treatment in ChildrenCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03707977Written as 10-1074
- A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionActive, not recruitingPhase 2Gilead SciencesNCT05729568Written as Zinlirvimab
- 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)CompletedPhase 1Rockefeller UniversityNCT05245292Written as 10-1074-LS
- 3BNC117 and 10-1074 in ART-treated IndividualsCompletedPhase 1Rockefeller UniversityNCT03526848Written as 10-1074
- Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 InfectionCompletedPhase 1Gilead SciencesNCT04811040Written as Zinlirvimab
- Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATIWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT05079451Written as 10-1074-LS
- 3BNC117-LS and 10-1074-LS in Viremic HIV-infected IndividualsCompletedPhase 1Rockefeller UniversityNCT04250636Written as 10-1074-LS
- Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIVCompletedPhase 2University of AarhusNCT03837756Written as 3BNC117 and 10-1074
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03928821Written as 10-1074
- Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected IndividualsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03571204Written as 3BNC117 and 10-1074
- Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment InterruptionsTerminatedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03831945Written as 10-1074
- 3BNC117 and 10-1074 in HIV Uninfected AdultsCompletedPhase 1Rockefeller UniversityNCT02824536Written as 10-1074
Given in every arm · 5 — zinlirvimab is usual care beside what is tested
- bNAbs and Anti-PD-1 in HIVNot yet recruitingPhase 2Ole Schmeltz SøgaardNCT07820813Written as 10-1074-LS
- Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionActive, not recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT04340596Written as 10-1074
- First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LSCompletedPhase 1Rockefeller UniversityNCT03554408Written as 10-1074-LS
- Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)Status unknownPhase 1Luis MontanerNCT03588715Written as 3BNC117 + 10-1074
- 3BNC117 and 10-1074 in HIV-infected IndividualsCompletedPhase 1Rockefeller UniversityNCT02825797Written as 10-1074
Codes
What other systems call zinlirvimab · ClinicalTrials.gg INT017158
- UNII (FDA) L98LJF15I9ZINLIRVIMABOne source FDA
- NCI Thesaurus C188593ZinlirvimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L98LJF15I9 | ZINLIRVIMAB | One source FDA |
| NCI Thesaurus | C188593 | Zinlirvimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.